Laropiprant

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Laropiprant
Accession Number
DB11629
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

Structure
Thumb
Synonyms
Not Available
External IDs
MK-0524
Categories
UNII
G7N11T8O78
CAS number
571170-77-9
Weight
Average: 435.89
Monoisotopic: 435.0707351
Chemical Formula
C21H19ClFNO4S
InChI Key
NXFFJDQHYLNEJK-CYBMUJFWSA-N
InChI
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
IUPAC Name
2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1H,2H,3H,4H-cyclopenta[b]indol-3-yl]acetic acid
SMILES
CS(=O)(=O)C1=C2N(CC3=CC=C(Cl)C=C3)C3=C(CC[C@@H]3CC(O)=O)C2=CC(F)=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
8043333
BindingDB
50205275
ChEBI
135942
ChEMBL
CHEMBL426559
PharmGKB
PA166129564
Wikipedia
Laropiprant

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcne Rosacea1
1CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Mixed hypercholesterolemia1
1CompletedTreatmentDyslipidemias2
1CompletedTreatmentHigh Cholesterol1
1CompletedTreatmentType 2 Diabetes Mellitus1
1TerminatedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Heterozygous Familial Hypercholesterolemia1
2CompletedTreatmentDyslipidemias1
2CompletedTreatmentFacial Flushing1
2CompletedTreatmentHigh Cholesterol1
3CompletedPreventionCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Peripheral Arterial Disease (PAD)1
3CompletedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Mixed hypercholesterolemia3
3CompletedTreatmentDyslipidemias1
3CompletedTreatmentHigh Cholesterol / Hyperlipidemias2
3CompletedTreatmentType 2 Diabetes Mellitus1
3TerminatedTreatmentDyslipidemia (Fredrickson Type Ⅱa)1
3TerminatedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Dyslipidemias1
3TerminatedTreatmentDyslipidemia (Fredrickson Type Ⅱa) / Mixed hypercholesterolemia2
3Unknown StatusTreatmentHigh Cholesterol1
3WithdrawnTreatmentDyslipidemias1
4CompletedPreventionDyslipidemias / Type 2 Diabetes Mellitus1
4CompletedTreatmentCoronary Heart Disease (CHD)1
4CompletedTreatmentHigh Cholesterol2
4CompletedTreatmentPolycystic Ovaries Syndrome1
4TerminatedTreatmentAtherosclerosis / Human Immunodeficiency Virus (HIV)1
4TerminatedTreatmentCoronary Artery Disease / Dyslipidemias2
4TerminatedTreatmentHyperlipoproteinemias / Metabolic Syndromes1
4Unknown StatusTreatmentDyslipidemias1
Not AvailableTerminatedNot AvailableHigh Cholesterol / Mixed hypercholesterolemia1
Not AvailableTerminatedBasic SciencePeripheral Arterial Disease (PAD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00428 mg/mLALOGPS
logP3.58ALOGPS
logP3.87ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)3.98ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area76.37 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.33 m3·mol-1ChemAxon
Polarizability42.76 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolyl carboxylic acids and derivatives
Direct Parent
Indolyl carboxylic acids and derivatives
Alternative Parents
3-alkylindoles / N-alkylindoles / Chlorobenzenes / Substituted pyrroles / Aryl chlorides / Aryl fluorides / Sulfones / Heteroaromatic compounds / Azacyclic compounds / Carboxylic acids
show 8 more
Substituents
Indolyl carboxylic acid derivative / N-alkylindole / 3-alkylindole / Indole / Chlorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Monocyclic benzene moiety
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 17, 2016 15:26 / Updated on September 02, 2019 19:28